CN1130223C - 包含生长激素,氨基酸和非离子去污剂的药物配方 - Google Patents

包含生长激素,氨基酸和非离子去污剂的药物配方 Download PDF

Info

Publication number
CN1130223C
CN1130223C CN97194040A CN97194040A CN1130223C CN 1130223 C CN1130223 C CN 1130223C CN 97194040 A CN97194040 A CN 97194040A CN 97194040 A CN97194040 A CN 97194040A CN 1130223 C CN1130223 C CN 1130223C
Authority
CN
China
Prior art keywords
growth hormone
amino acid
histidine
amount
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN97194040A
Other languages
English (en)
Chinese (zh)
Other versions
CN1216472A (zh
Inventor
S·比约恩
H·H·索伦森
P·朗巴勒
S·M·拉尔森
K·爱比霍
B·L·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN1216472A publication Critical patent/CN1216472A/zh
Application granted granted Critical
Publication of CN1130223C publication Critical patent/CN1130223C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN97194040A 1996-04-24 1997-04-24 包含生长激素,氨基酸和非离子去污剂的药物配方 Expired - Lifetime CN1130223C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0490/96 1996-04-24
DK49096 1996-04-24
DK0490/1996 1996-04-24

Publications (2)

Publication Number Publication Date
CN1216472A CN1216472A (zh) 1999-05-12
CN1130223C true CN1130223C (zh) 2003-12-10

Family

ID=8094154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194040A Expired - Lifetime CN1130223C (zh) 1996-04-24 1997-04-24 包含生长激素,氨基酸和非离子去污剂的药物配方

Country Status (20)

Country Link
US (1) US20020077461A1 (cg-RX-API-DMAC7.html)
EP (2) EP0904099B1 (cg-RX-API-DMAC7.html)
JP (2) JP4176834B2 (cg-RX-API-DMAC7.html)
KR (1) KR20000010630A (cg-RX-API-DMAC7.html)
CN (1) CN1130223C (cg-RX-API-DMAC7.html)
AT (1) ATE309819T1 (cg-RX-API-DMAC7.html)
AU (1) AU733592B2 (cg-RX-API-DMAC7.html)
BR (1) BR9708858A (cg-RX-API-DMAC7.html)
CA (1) CA2252535C (cg-RX-API-DMAC7.html)
CZ (1) CZ298292B6 (cg-RX-API-DMAC7.html)
DE (1) DE69734653T2 (cg-RX-API-DMAC7.html)
DK (1) DK0904099T3 (cg-RX-API-DMAC7.html)
ES (1) ES2253774T3 (cg-RX-API-DMAC7.html)
HU (1) HU229868B1 (cg-RX-API-DMAC7.html)
IL (2) IL126463A0 (cg-RX-API-DMAC7.html)
NO (1) NO323360B1 (cg-RX-API-DMAC7.html)
PL (1) PL188222B1 (cg-RX-API-DMAC7.html)
RU (1) RU2236250C2 (cg-RX-API-DMAC7.html)
UA (1) UA66758C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997039768A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
DE69826705T2 (de) * 1997-11-12 2006-02-23 Alza Corp., Palo Alto Verfahren zur dermalen verabreichung von polypeptiden
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
CA2516314C (en) * 2003-03-18 2012-01-03 Ares Trading Sa Liquid growth hormone formulation and process of preparation thereof
JP4909071B2 (ja) * 2003-03-24 2012-04-04 プルーローメッド， インコーポレイテッド 逆感熱性ポリマーを使用する一時的な塞栓形成
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7700086B2 (en) * 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
WO2005063298A1 (en) * 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
AU2005237775B2 (en) * 2004-04-07 2010-03-04 Ares Trading S.A. Liquid growth hormone formulation
EP1833993A4 (en) * 2004-12-22 2009-07-22 Ambrx Inc HUMAN GROWTH HORMONE FORMULATIONS COMPRISING AN AMINO ACID CODED NON-NATURALLY
ZA200704926B (en) * 2004-12-22 2008-12-31 Ambrx Inc Modified human growth hormone
KR20070090023A (ko) * 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
RU2008105545A (ru) 2005-08-30 2009-10-10 Ново Нордиск Хелс Кеа Аг (Ch) Жидкие препараты пэгилированного гормона роста
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
ES2605022T3 (es) * 2006-07-06 2017-03-10 Daewoong Co., Ltd. Una formulación líquida estable de la hormona del crecimiento humana
JP5252458B2 (ja) 2006-07-07 2013-07-31 ノボ ノルディスク ヘルス ケア アーゲー 新規タンパク質コンジュゲート及びその製造方法
WO2008076819A2 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101935334B1 (ko) * 2010-09-21 2019-01-04 훼링 비.브이. 재조합 인체성장호르몬(ｈＧＨ)를 제조하는 개선된 방법
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
CN114288254A (zh) * 2013-09-27 2022-04-08 韩美药品株式会社 长效人生长激素缀合物的制剂
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
KR102744951B1 (ko) 2016-03-28 2024-12-23 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
JP7188944B2 (ja) 2017-09-07 2022-12-13 Ｊｃｒファーマ株式会社 水性医薬組成物
AU2018342471B2 (en) 2017-09-27 2023-08-24 Incyte Corporation Salts of pyrrolotriazine derivatives useful as TAM inhibitors
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN115634284B (zh) * 2022-10-31 2025-02-11 景泽生物医药(合肥)股份有限公司 一种促性腺激素冻干制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1994003198A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
CA2125855C (en) * 1991-12-20 2008-05-13 Hans Holmegaard Sorensen A stabilized pharmaceutical formulation comprising growth hormone and histidine
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat

Also Published As

Publication number Publication date
HU229868B1 (en) 2014-10-28
CA2252535A1 (en) 1997-10-30
US20020077461A1 (en) 2002-06-20
CN1216472A (zh) 1999-05-12
CA2252535C (en) 2009-06-23
ES2253774T3 (es) 2006-06-01
BR9708858A (pt) 1999-08-03
AU2634397A (en) 1997-11-12
PL188222B1 (pl) 2004-12-31
NO323360B1 (no) 2007-04-10
ATE309819T1 (de) 2005-12-15
CZ298292B6 (cs) 2007-08-15
IL126463A (en) 2007-06-17
RU2236250C2 (ru) 2004-09-20
EP0904099B1 (en) 2005-11-16
EP0904099A1 (en) 1999-03-31
WO1997039768A1 (en) 1997-10-30
DE69734653T2 (de) 2006-08-10
IL126463A0 (en) 1999-08-17
DK0904099T3 (da) 2006-03-06
EP1629832A1 (en) 2006-03-01
HUP9902476A2 (hu) 2000-11-28
PL329386A1 (en) 1999-03-29
NO984951D0 (no) 1998-10-23
DE69734653D1 (de) 2005-12-22
UA66758C2 (en) 2004-06-15
AU733592B2 (en) 2001-05-17
CZ320798A3 (cs) 1999-03-17
HUP9902476A3 (en) 2000-12-28
JP4176834B2 (ja) 2008-11-05
NO984951L (no) 1998-10-23
JP2008231124A (ja) 2008-10-02
JP2000508665A (ja) 2000-07-11
KR20000010630A (ko) 2000-02-25

Similar Documents

Publication Publication Date Title
CN1130223C (zh) 包含生长激素,氨基酸和非离子去污剂的药物配方
CN1190897A (zh) 含有用锌及选择性的赖氨酸或者钙离子预处理过的生长激素的稳定药物组合物
US5851992A (en) Treatment of growth hormone deficiency
CN1132626C (zh) 稳定化的生长激素制剂和其制备方法
US5654278A (en) Composition and method comprising growth hormone and leucine
US8841252B2 (en) Pharmaceutical formulation
JPH10511965A (ja) 成長ホルモン及びＬｅｕ−Ｈｉｓ−Ｌｅｕを含む安定化医薬製剤
JP4064454B2 (ja) 成長ホルモンおよびイソロイシンを含んでなる医薬製剤
JP4064453B2 (ja) 成長ホルモンおよびバリンを含んでなる医薬製剤
JP4064455B2 (ja) 成長ホルモンおよびロイシンを含んでなる医薬製剤
US5552385A (en) Pharmaceutical formulation
US20030162711A1 (en) Pharmaceutical formulation
CN1190896A (zh) 包括生长激素和包括至少一种碱性氨基酸残基和至少一种酸性氨基酸残基肽的稳定的药物制剂
AU4329596A (en) A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
JPH10511963A (ja) 成長ホルモン及びＬｙｓ−Ｘを含む安定化医薬製剤
MXPA98008786A (en) A pharmaceutical formulation containing a growth hormone, an amino acid and a non-ion detergent
MXPA98000309A (en) Stabilized pharmaceutical formulation comprising a hormone of growth and a peptide that comprises at least one residue of basic amino acid and at least one waste of aminoacido ac
MXPA98000358A (en) Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NOVO NORDISK HEALTH CARE AG

Free format text: FORMER OWNER: NOVO NORDISK A/S

Effective date: 20111011

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: Denmark bagsvaerd

Patentee after: NOVO NORDISK A/S

Address before: The Danish Bagh division ward

Patentee before: Novo Nordisk A/S

TR01 Transfer of patent right

Effective date of registration: 20111011

Address after: Zurich

Patentee after: NOVO NORDISK HEALTH CARE AG

Address before: Denmark bagsvaerd

Patentee before: Novo Nordisk A/S

CX01 Expiry of patent term

Granted publication date: 20031210

CX01 Expiry of patent term